Novel CUL7 biallelic mutations alter the skeletal phenotype of 3M syndrome

Nao Takizaki1, Yoshinori Tsurusaki2, Kaoru Katsumata3, Yumi Enomoto2, Hiroaki Murakami1, Koji Muroya4, Hiroshi Ishikawa5, Noriko Aida6, Gen Nishimura7 and Kenji Kurosawa1,2

Abstract

3M syndrome is an autosomal recessive disorder characterized by severe growth retardation, distinct facial features, and skeletal changes, including long slender tubular bones and tall vertebral bodies. We report a Japanese patient with 3M syndrome caused by the biallelic novel variants c.1705_1708del and c.1989_1999del of CUL7. Skeletal features were consistent with 3M syndrome in the early neonatal period but became less obvious by 2 years of age.

3M syndrome (MIM #273750) is a rare autosomal recessive disorder characterized by severe growth retardation, distinct facial features, and skeletal changes. Skeletal manifestations include long slender tubular bones and tall vertebral bodies. Causative germline biallelic mutations have been identified in the cullin 7 (CUL7) (MIM #273750), obscurin like 1 (OBSL1) (MIM #612921), and coiled-coil domain containing 8 (CCDC8) (MIM #614205) genes. CUL7 encodes a component of an E3 ubiquitin-protein ligase complex. In brief, CUL7 interacts with the tumor suppressor protein p53, cullin 9 (CUL9), and F-box and WD repeat domain containing 8 (FBXW8) proteins, leading to the regulation of microtubules and genome stability.

Here, we report a patient with novel compound heterozygous mutations who developed less-severe distinct skeletal features during the neonatal period until 2 years of age.

The proband was a 1-year-old Japanese boy born to nonconsanguineous parents with no family history of bone dysplasia. Fetal ultrasonography showed a severely short femur of 21 mm (−2.6 SD) at 19 weeks. Progressive fetal growth retardation suggested skeletal dysplasia at 21 weeks of gestation. At 28 weeks, severe shortening of the femur with −5 SD, relative macrocephaly, and short thorax were noted (Fig. 1a).

He was born at 39 weeks of gestation by emergency cesarean section because of his non-reassuring fetal status. His birth weight was 2007 g (−3.5 SD), length was 39.0 cm (−4.8 SD), occipital frontal circumference was 34 cm (+0.6 SD), and chest circumference was 26 cm. Apgar scores were 8/9. Physical examination at birth revealed a phenotype of relative macrocephaly, triangular face with low nasal root, short neck, and short limbs with prominent heels. Concomitantly, a bone survey at birth revealed tall vertebral bodies and slender long bones (Fig. 1b–d). He spent 3 days in the neonatal intensive care unit with no medical support and was discharged to his mother on day 8. Notably, at 1 year and 3 months, reevaluation of skeletal X-rays showed mild manifestations for typical 3M syndrome compared with those observed at birth (Fig. 1e, f).

At the age of 1 year and 10 months, his weight was 6180 g (−4.3 SD), length was 62.8 cm (−7.3 SD), occipital frontal circumference was 46.5 cm (−1.1 SD), and chest circumference was 31.4 cm (Fig. 1g). According to the expected developmental milestones, the patient demonstrated mild developmental delay for his age, with eye contact at 4 months, rolling over at 8 months, sitting without support for 10 months, and speaking meaningful words and walking without support at 15 months.
Clinical information was collected after obtaining written informed consent from the patient's family. This study was approved by the institutional review board of Kanagawa Children's Medical Center. Genomic DNA was extracted from the peripheral blood of the patient and both parents using the QIAcube Kit (QIAGEN, Hilden, Germany) according to the manufacturer's instructions. Targeted resequencing was performed for the affected patient. Genomic DNA captured by the TruSight One Sequencing Panel (Illumina, San Diego, CA, USA) was sequenced on the MiSeq platform (Illumina) with 151-base pair paired-end reads as previously described. Candidate variants were confirmed by Sanger sequencing.

We identified the compound heterozygous variants NM_014780.4:c.1705_1708del:p.(Gly569Leufs*4) and c.1989_1999del:p.(Gln664Glyfs*12) of CUL7. Sanger sequencing confirmed that the c.1705_1708del variant was inherited from the father, whereas the c.1989_1999del variant was inherited from the mother (Fig. 2). These variants were novel and are not included in the public databases gnomAD, Tombo, ClinVar, Human Genetic Variation Database, and Human Genome Mutation Database 2019.4. Both identified CUL7 variants were predicted to result in a premature termination codon consistent with biallelic loss-of-function mutations.

The prenatal growth patterns of 3M syndrome are associated with severe limb shortening. Of the proband exhibited the cardinal skeletal features of 3M syndrome during both the prenatal and neonatal periods, his skeletal features of long tubular bones and tall vertebral bodies were less apparent by 2 years of age. This indicates that normalization of skeletal features, particularly the shape of vertebral bodies, can occur over 1 year of age.
There are generally no genotype-to-phenotype correlations in patients with 3M syndrome. Skeletal changes and growth patterns are variable, even in the same family. In agreement with these reports, our results suggest that the skeletal features of 3M syndrome vary depending on the patient’s developmental age and motor functions.

CUL7 consists of 1698 amino acids. CUL7 has a DOC1 domain and C-terminated Cullin domain associated with FBXW8 binding and ROC1 binding, contributing to mitosis and cytokinesis. Aberrant transcripts of trun-
cating CUL7 variants are expressed in the fibroblasts of patients. Although we could not assess the transcripts from both abnormal alleles, the biallelic loss-of-function mutations in CUL7 in our patient were believed to perturb mitosis and cytokinesis, resulting in the 3M syndrome phenotype.

In conclusion, we identified novel truncating mutations of CUL7 in a Japanese patient with 3M syndrome. Skeletal surveys revealed changing manifestations with progressively less-distinct features of the long bones and vertebrae from the neonatal to early infantile period by 2 years of age. To understand the mechanisms of these changes and observed variability in the growth patterns during the pre- and postnatal periods with or without growth hormone treatment, further studies combined with skeletal surveys and growth curve analysis of patients with 3M syndrome are required.

Acknowledgements
We thank the patient and his family for participating in this research. This work was supported by Research on Rare and Intractable Diseases from the Ministry of Health, Labour and Welfare, Japan and the Initiative on Rare and Undiagnosed Diseases (IRUD) (18ek0109301) from the Japan Agency for Medical Research and Development (AMED) and JSPS KAKENHI 17K10069 (KK).

HGV database
The relevant data from this Data Report are hosted at the Human Genome Variation Database at https://doi.org/10.6084/m9.figshare.hgv.2808, https://doi.org/10.6084/m9.figshare.hgv.2805.

Conflict of interest
The authors declare that they have no conflict of interest.

References
1. Hennekam, R. C. M., Bijlsma, J. B. & Spranger, J. Further delineation of the 3-M syndrome with review of the literature. Am. J. Med. Genet. 28, 196–209 (1987).
2. Huber, C. et al. Identification of mutations in CUL7 in 3-M syndrome. Nat. Genet. 37, 1119–1124 (2005).
3. Hanson, D. et al. The primordial growth disorder 3-M syndrome connects ubiquitination to the cytoskeletal adaptor OBSL1. Am. J. Hum. Genet. 84, 801–806 (2009).
4. Hanson, D. et al. Exome sequencing identifies CCDC8 mutations in 3-M syndrome, suggesting that CCDC8 contributes in a pathway with CUL7 and OBSL1 to control human growth. Am. J. Hum. Genet. 89, 148–153 (2011).
5. Li, Z. et al. CUL9 mediates the functions of the 3M complex and ubiquitylates survivin to maintain genome integrity. Mol. Cell 54, 805–819 (2014).
6. Yan, J. et al. The 3M complex maintains microtubule and genome integrity. Mol. Cell 54, 791–804 (2014).
7. Sato, Y. et al. Novel COL4A1 mutation in a fetus with early prenatal onset of schizencephaly. Hum. Genome Var. 5, 4 (2018).
8. Lugli, L. et al. Pre- and post-natal growth in two sisters with 3-M syndrome. Eur. J. Med. Genet. 59, 232–236 (2016).
9. Huber, C., Munnich, A. & Corrimer-Dare, V. The 3M syndrome. Best. Pract. Res. Clin. Endocrinol. Metab. 25, 143–151 (2011).
10. Al-Dosari, M. S. et al. 3M syndrome: an easily recognizable yet underdiagnosed cause of proportionate short stature. J. Pediatr. 161, 139–45.e1 (2012).
11. Deeb, A., Afandi, O., Attia, S. & Fatih, A. E. 3-M syndrome: a novel CUL7 mutation associated with respiratory distress and a good response to GH therapy. Endocrinol. Diabetes Metab. Case Rep. 2015, 150012 (2015).